Mesoblast Limited (NASDAQ:MESO) is anticipated to report earnings of 45.50% per share for next year, according to research brokerages covering the stock. Analysts are expecting an EPS change of 20.60% for the current year. Wall Street analysts polled by Thomson Reuters have a current recommendation of 2.10 on a consensus basis for the stock. The same analysts see shares reaching $13.29 within the next year on a consensus basis.
Let’s take a look at how the stock has been performing recently. Over the past twelve months, Mesoblast Limited (NASDAQ:MESO)’s stock was 35.14%. Over the last week of the month, it was 17.56%, -4.74% over the last quarter, and -32.93% for the past six months.
Over the past 50 days, Mesoblast Limited stock’s -3.08% off of the high and 36.67% removed from the low. Their 52-Week High and Low are noted here. -42.16% (High), 80.48%, (Low).
Earnings Per Share (EPS) is the earnings made by a company divided by their number of shares. EPS enables the earnings of a company to easily be compared to their competitors. The higher the number, the more profit per dollar is being made on investor capital. Mesoblast Limited’s EPS for the trailing 12 months is -1.00. Their EPS should be compared to other companies in the Healthcare sector.
Technical analysts have little regard for the value of a company. They use historic price data to observe stock price patterns to predict the direction of that price going forward. Analysts use common formulas and ratios to accomplish this.
Mesoblast Limited (NASDAQ:MESO)’s RSI (Relative Strength Index) is 70.71. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions.